文献速递前列腺癌

精准肿瘤学时代转移性去势抵抗性前列腺癌全身治疗进展

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
PubMed 文献 · Eur Urol · 2018-04-16

除多西他赛外,阿比特龙、恩扎卢胺、卡巴他赛、镭-223和sipuleucel-T在III期试验中显示生存获益。PARP抑制剂和PD-1抑制剂等基因靶向药物正在研究中,患者选择和最佳序贯策略仍不明确。

要点

  • mCRPC已有多种全身治疗选择,包括激素治疗、化疗、免疫治疗、放射性核素治疗及骨改良药物。
  • 生物标志物如HRR突变、MMR突变和AR剪接变异体7可能辅助患者选择,但最佳序贯策略未明。
  • PARP抑制剂和PD-1抑制剂等基因靶向药物在生物标志物筛选亚组中前景可期。

核心结论

  • mCRPC新药涌现极大改善了治疗选择,但患者选择和最佳序贯使用以实现最长累积生存获益并防止早期耐药的策略仍不明确。

主要发现

  • 除多西他赛外,阿比特龙、恩扎卢胺、卡巴他赛、镭-223和sipuleucel-T在III期试验中显示生存获益。
  • 镭-223和地舒单抗增加了骨转移管理选择。
  • 下一代AR轴靶向治疗、免疫治疗及靶向其他致癌和基因组通路的疗法(尤其PARP抑制剂和PD-1抑制剂)正在临床研究中。
  • 预测性生物标志物(同源重组修复突变、错配修复突变、AR剪接变异体7)信息开始涌现。
  • 在去势敏感状态早期使用活性药物可能改变疾病进展为去势抵抗时的临床管理。

关键数值与推荐

  • mCRPC全身治疗选择包括激素治疗、化疗、免疫治疗、放射性核素治疗以及骨改良药物和姑息或支持措施。
  • PARP抑制剂和PD-1抑制剂等新型基因靶向药物针对特定生物标志物筛选亚组患者。

临床怎么用

  • 临床医生应了解mCRPC多种全身治疗选择及其生存获益,根据患者情况选择治疗。
  • 生物标志物检测(如HRR突变、MMR突变、AR-V7)可能有助于个体化治疗选择,但最佳序贯策略需进一步研究。

局限性

  • 患者选择、有效序贯使用和耐药模式的理解仍不完整。
  • 最佳患者选择和最佳序贯使用以实现最长累积生存获益并防止早期耐药的策略仍不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Introduction of novel agents for the management of advanced prostate cancer provides a range of treatment options with notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At the same time, understanding of optimal patient selection, effective sequential use, and development of resistance patterns remains incomplete. OBJECTIVE: To review current systemic therapies and recent advances in drug development for mCRPC and strategies to aid in patient selection and optimal sequencing. EVIDENCE ACQUISITION: A literature review of PubMed/Medline, Cochrane Library, Current Contents Medicine, Web of Science, Clinical Trial.Gov, WHO-ICTRP (January 2004-November 2017), and the proceedings of major international meetings (2015/2016/2017) was performed in November 2017. EVIDENCE SYNTHESIS: In the last few years, several new options for treatment of mCRPC have shown a survival benefit in phase III trials besides docetaxel:abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T. Radium-223 and denosumab have increased options in management of bone metastases. Currently, novel agents such as next-generation androgen receptor (AR) axis-targeting treatments, immunotherapeutics, or therapies targeting other oncogenic and genomic pathways, particularly poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors and PD-1 inhibitors, are under clinical investigation. With increasing treatment options for mCRPC, information on how to personalize management and how to select and sequence existing therapies is beginning to emerge, as are predictive biomarkers (homologous repair mutations, mismatch repair mutations, AR splice variant 7). Finally, early use of active agents in the castration-sensitive state will likely also change the clinical management of the disease when it becomes castrate resistant. CONCLUSIONS: The emergence of new drugs for mCRPC has improved treatment options dramatically. Currently, systemic treatment options for mCRPC include hormonal therapy, chemotherapy, immunotherapy, and radionuclide therapy as well as bone-modifying agents and palliative or supportive measures. Further, new genetically targeted agents (PARP inhibitors and PD-1 inhibitors) are on the horizon for certain subsets of biomarker-selected patients. The best strategies for patient selection and optimal sequential use to achieve the longest cumulative survival improvement and to prevent early resistance remain unclear. PATIENT SUMMARY: The current literature and proceedings from relevant congresses related to available systemic agents for the treatment of metastatic castration-resistant prostate cancer, including novel genetically targeted therapies, including poly(adenosine diphosphate-ribose) polymerase inhibitors and PD-1 inhibitors, were reviewed. Current therapies and ongoing developments are discussed.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nuhn P, De Bono JS, Fizazi K, et al. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2018. PMID: 29673712. doi:10.1016/j.eururo.2018.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。